celecoxib has been researched along with Tuberous Sclerosis in 1 studies
Tuberous Sclerosis: Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H | 1 |
| Jin, F | 1 |
| Jiang, K | 1 |
| Ji, S | 1 |
| Wang, L | 1 |
| Ni, Z | 1 |
| Chen, X | 1 |
| Hu, Z | 1 |
| Zhang, H | 1 |
| Liu, Y | 1 |
| Qin, Y | 1 |
| Zha, X | 1 |
1 other study available for celecoxib and Tuberous Sclerosis
| Article | Year |
|---|---|
mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Celecoxib; Cell Proliferati | 2016 |